251 related articles for article (PubMed ID: 30251407)
1. Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer.
Chen J; Sang Z; Jiang Y; Yang C; He L
Chem Biol Drug Des; 2019 Mar; 93(3):232-241. PubMed ID: 30251407
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity.
Khetmalis YM; Fathima A; Schweipert M; Debarnot C; Bandaru NVMR; Murugesan S; Jamma T; Meyer-Almes FJ; Sekhar KVGC
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446224
[TBL] [Abstract][Full Text] [Related]
5. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
[TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
9. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
11. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
14. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
19. Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation.
Xu X; Zhang D; Zhao T; Wang M; Li Y; Du Q; Kou J; Li Z; Bian J
Eur J Med Chem; 2022 Apr; 233():114228. PubMed ID: 35245830
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
